Re­gen­eron aims to stop mus­cle loss with com­bi­na­tion treat­ment ap­proach in obe­si­ty

Re­gen­eron re­it­er­at­ed its plans to jump in­to the weight loss race in 2024, ex­pect­ing to start test­ing a com­bi­na­tion of its mus­cle-pre­serv­ing drugs with semaglu­tide, the ac­tive in­gre­di­ent in No­vo Nordisk’s Ozem­pic and We­govy.

The $105 bil­lion New York biotech said it an­tic­i­pates start­ing a Phase II study in mid-2024 that will test a range of dif­fer­ent dos­es and com­bi­na­tions of semaglu­tide, trevo­grum­ab (an an­ti-myo­statin an­ti­body) and gare­tos­mab (an an­ti-ac­tivin A an­ti­body). George Yan­copou­los, Re­gen­eron’s chief sci­en­tif­ic of­fi­cer, high­light­ed the loss of mus­cle as a con­cern­ing side ef­fect of obe­si­ty treat­ments like Ozem­pic and Eli Lil­ly’s Zep­bound.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER